References

EIIP/AQVN references published by members of the Biomed Protection Team

 

Top rated articles

Papers in the top 2% of all research outputs ever according to Altmetric:

altmetric_66 Altmetric score 66

Schmier S, Mostafa A, Haarmann T, Bannert N, Ziebuhr J, Veljkovic V, Dietrich U, Pleschka S. In Silico Prediction and Experimental Confirmation of HA Residues Conferring Enhanced Human Receptor Specificity of H5N1 Influenza A Viruses. Sci Rep. 2015;5:11434.

 

altmetric_45 Altmetric score 45

Veljkovic V, Glisic S, Veljkovic N, Bojic T, Dietrich U, Perovic VR, Colombatti A. Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism. Vaccine 2014; 32:6569

 

Papers in the top 10% of all research outputs ever according to Altmetric:

Altmetric score 15

Veljkovic V, Goeijenbier M, Glisic S, Veljkovic N, Perovic VR, Sencanski M, Branch DR, Paessler S. In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease. F1000Res. 2015;4:104.

 
 

Monographs

  • Veljković V. Theoretical approach to preselection of cancerogens and chemical carcinogenesis. Gordon & Breach, New York (1980).
  • Veljkovic V., Jevtovic Dj. Physical exercise in prevention and therapy of AIDS and cancer. Monada, Belgrade (1999).
  • Ho MW, Burcher S, Gala R, Velkovic V. Unraveling Aids: The Independent Science And Promising Alternative Therapies. Vital Health Pub., Ridgefield (2005).

 
 

Selected articles published in international journals

  1. Veljkovic V., Slavic I. Simple general-model pseudopotential. Phys. Rev. Let., 29, 105 (1972).
  2. Veljkovic V. The dependence of the Fermi energy on the atomic number. Phys. Lett., 45A, 41 (1973).
  3. Veljkovic V., Lalovic D. General model pseudopotential for positive ions. Phys. Lett., 45A, 59 (1973).
  4. Veljkovic V., Tosic B., Janjic J., Chemical bond in intermetallic compounds and its influence on electrical properties. Scr. Metall., 9, 459 (1975).
  5. Blazon M., Stanojevic B., Veljkovic V., Effect of alloying elements on the formation of boride layer on steel. Scr. Metall., 9, 1153 (1975).
  6. Veljkovic V., Lalovic D., Superconductivity and the periodic system. Phys. Rev., 11, 4242 (1975).
  7. Veljkovic V., Lalovic D., Theoretical prediction of mutagenicity and carcinogenicity of chemical substances. Cancer Biochem. Biophys., 1, 295 (1976).
  8. Veljkovic V., Lalovic D., Simple theoretical criterion of chemical carcinogenesis. Experientia, 33, 1228 (1977).
  9. Veljkovic V., Lalovic D., Correlation between the carcinogenicity of organic substances and their spectral characteristics. Experientia, 34, 1342 (1977).
  10. Veljkovic V., Ajdacic V., Cytostatic activity of organic compounds and their average quasivalence number. Experientia, 34, 639 (1977).
  11. Ajdacic V., Veljkovic V. Antibiotic activity of organic compounds and their average quasivalence number. Experientia, 34, 633 (1977).
  12. Vukajlovic F., Zekovic S., Veljkovic V., Resistivity calculations for liquid metals. Physica, 92B, 66 (1977).
  13. Davidovic M., Vukajlovic F., Zekovic S., Veljkovic V. The temperature dependence of the resistivity of liquid lead. Phil. Mag., 36, 1257 (1977).
  14. Veljkovic V., Janjic J., Tosic B. Ion-ion interaction and superconductivity of metals and intermetallic compounds. J. Mater. Sci., 13, 1138 (1978).
  15. Zekovic S., Vukajlovic F., Veljkovic V. Phonon spectra of alkali metals,Physica, 114B, 316 (1982).
  16. Veljkovic V., Cosic I., Dimitrijevic B., Lalovic D., Is it possible to analyze DNA and protein sequence by the method of digital signal processing?. IEEE Trans., BME-32, 337 (1985).
  17. Veljkovic V., Cosic I., A novel method of protein analysis for prediction of biological function. Cancer Biochem. Biophys., 9, 139 (1987).
  18. Veljkovic V., Lalovic D., A stoichiometry criterion for high Tc superconductors. Phys. Lett. A, 142 , 528 (1989).
  19. Veljkovic V., Lalovic D. The global average DNA base composition of coding regions may be determined by the electron-ion interaction potential. Biosystems, 23, 311 (1990).
  20. Ivanovic V., Demajo M., Todorovic-Rakovic N., Nikolic-Vukosavljevic D., Neskovic-Konstantinovic Z., Krtolica K., Veljkovic V., Prljic J., Dimitrijevic B. Localization of recognition site between transforming growth factor-b1 (TGF-b1) and TGFb-receptor type II: possible implications in breast cancer. Med. Hypoth. 2004; 62: 727-732.
  21. Veljkovic V., Metlas R., Identification of nanopeptide from HTLV3,LAV and ARV-2 envelope gp120 determining binding to T4 cell surface protein. Cancer Biochem. Biophys., 10, 191 (1988).
  22. Veljkovic V., Metlas R., Sequence similarity between HIV-1 envelope protein gp120 and human proteins: a new hypothesis on protective antibody production. Immunol. Lett., 26, 193 (1990).
  23. Metlas R., Veljkovic V., Paladini R., Pongor S., Protein and DNA sequence similarity between the V3 loop of HIV-1 envelope protein gp120 and immunoglobulin variable region. Biochem. Biophys. Res.Commun., 179, 1056 (1991).
  24. Veljkovic V., Metlas R., Identification of immunoglobulin recombination elements in in HIV-1 envelope gene. Immunol.Lett., 31, 11 (1991).
  25. Veljkovic V., Metlas R., HIV and idiotypic T-cel regulation: another view., Immunol. Today, 15, 39 (1992).
  26. Veljkovic V., Metlas R., Raspopovic J., Pongor S., Spectral and sequence similarity between VIP and the second conserved region of HIV envelope glycoprotein gp120: possible consequences on prevention and therapy of AIDS., Biochem. Biophys. Res. Commun., 189, 705(1992).
  27. Veljkovic V., Metlas R., Potentially negative effects of AIDS vaccines Based on recombinant viruses carrying HIV-1 derived envelope gene: a warning on AIDS vaccine development., Vaccine, 11, 291 (1993).
  28. Veljkovic V., Metlas R., Vojvodic D., Cavor Lj., Pejinovic N., Dujic A., Zakhariev S., Guarnaccia C., Pongor S., Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120., Biochem Biophys. Res. Commun. 196, 1019 (1993).
  29. Metlas R., Skerl V., Colombatti A., Pongor S., Veljkovic V. Reactivity of AIDS patients sera with peptide derived from HIV-1 NY5 gp120V3 loop and consensus sequence of collagens. AIDS Res. & Human Retrovir. 10, 1421 (1994).
  30. Metlas R., Skerl V., Veljkovic V., Colombatti A., Pongor S., Immunoglobulin-like domain of HIV-1 envelope glycoprotein gp120 encodes putative internal image of some common human proteins. Viral Immunol. 7, 215 (1994).
  31. Metlas R., Skerl V., Veljkovic V., Pongor S., Further evidence for the relationship between HIV-1 gp120 V3 loop and T cell receptor g-chain structures. Immunol. Lett. 47, 25 (1995).
  32. Veljkovic V., Johnson E., Metlas R. Analogy of HIV-1 to oncogenic viruses : implications for the pathogenesis of AIDS. Cancer J. 8, 308 (1995).
  33. Metlas R. Veljkovic V., Does HIV-1 gp120 manipulate human immune network. Vaccine 13, 355 (1995).
  34. Veljkovic V., Johnson E., Metlas R. Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120. Vaccine 15, 437 (1997).
  35. Prljic J., Veljkovic N., Doliana R., Colombatti A., Johnson E., Metlas R., Veljkovic V. Identification of the Chi recombinational hot spot within the HIV-1 gp120 gene: possible implications for the AIDS vaccine development. Vaccine, 17, 1462 (1999).
  36. Metlas R., Trajkovic D., Srdic T., Veljkovic V., Colombatti A. Human immunodeficency virus V3 peptide-reactive antibodies are present in normal HIV- negative sera. AIDS Res. Hum. Retrovir., 15, 671 (1999)
  37. Metlas R., Trajkovic D. Srdic T., Veljkovic V., Colombatti A. Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures. J. Acquir. Immune. Defic. Syndr., 21, 266 (1999).
  38. Veljkovic V., Metlas R., Kohler H, Urnovitz H., Prljic J., Veljkovic N., Johnson E., Muller S. AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. Vaccine, 19, 1855 (2001).
  39. Veljkovic V., Metlas R, Jevtovic V, Stringer WW. The Role of Passive Immunization in HIV+ Patients: A Case Report. Chest, 120, 662 (2001).
  40. Veljkovic V., Muller S, Kohler H Does VaxGen hide the breakthrough infections? Lancet. 361, 1743 (2003).
  41. Veljkovic V., Muller S, Kohler H. AIDSVAX results: an important open question. Vaccine, 21, 3528 (2003).
  42. Veljkovic N, Branch DR, Metlas R, Prljic J, Vlahovicek K, Pongor S, Veljkovic V. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease. J Pept Res, 62, 158 (2003).
  43. Veljkovic N., Metlas R., Prljic J., Manfredi R., Branch D., Stringer W. Veljkovic V. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease. J. Clin. Virol. 11, 39 (2004)
  44. Veljkovic V., Kohler H., Muller S. Aids vaccine: state of the art at the beginning of the third millennium. Int. Rev. Immunol.,23, 369 (2004).
  45. Veljkovic V., Veljkovic N., Metlas R. Molecular makeup of HIV-1 envelope protein. Int. Rev. Immunol., 23, 383 (2004).
  46. Metlas R., Veljkovic V. HIV-1 gp120 and immune network. Int. Rev. Immunol. 23, 413 (2004).
  47. Veljkovic V., Metlas R. Application of VIP/NTM reactive natural antibodies in therapy of HIV disease. Int. Rev. Immunol., 23, 437 (2004).
  48. Prljic J., Veljkovic N., Veljkovic V. Recombinant properties of the HIV-1 gp120 gene. Int. Rev. Immunol., 23, 447 (2004).
  49. Veljkovic V., Prljic J., Veljkovic T. Safety and ethical consideration of AIDS vaccine. Int. Rev. Immunol., 23, 465 (2004).
  50. Raicevic S., Wright J., Veljkovic V., Conca J. Theoretical stability assessment of uranyl phosphates and apatites: selection of amendments for in situ remediation of uranium. Sci Total Environ., 355, 13 (2006).
  51. Veljkovic V., Veljkovic N., Este J., Huther A., Dietrich U. Application of the EIIP/ISM bioinformatics concept in development of new drugs. Curr. Medic. Chem., 14, 441 (2007).
  52. Metlas R., Srdic T., Veljkovic V. Anti-IgG antibodies from sera of healthy individuals neutralize HIV-1 primary isolates. Curr. HIV Res., 5, 261 (2007).
  53. Veljkovic V., J.F. Mouscadet, Veljkovic N., Glisic S., Debyser Z. Simple criterion for selection of flavonoid compounds with anti-HIV activity. Bioorg. Medic. Chem. Lett., 17, 1226 (2007).
  54. Tintori C, Manetti F, Veljkovic N, Perovic V, Vercammen J, Hayes S, Massa S, Witvrow M, Debyser Z, Veljkoivic V, Botta M. Novel virtual screening protocol based on the combined use of molecular modeling and electron-ion interaction potential techniques to design HIV-1 integrase inhibitors. J Chem Inf Model., 47, 1536 (2007).
  55. Mugnaini C, Rajamaki S, Tintori C, Corelli F, Massa S, Witvrouw M, Debyser Z, Veljkovic V, Botta M. Toward novel HIV-1 integrase binding inhibitors: molecular modeling, synthesis, and biological studies. Bioorg Med Chem Lett., 17, 5370 (2007).
  56. Veljkovic V, Veljkovic N, Ho M. AIDS vaccine: efficacy, safety and ethics. Vaccine, 26: 3072 (2007).
  57. Doliana R, Veljkovic V, Prljic J, Veljkovic N, De Lorenzo E, Mongiati M, Ligresti g, Marastoni S, Colombatti A. EMILINs interact with anthrax protective antigen and Inhibit toxin action in vitro. Matrix Biol., 27, 96 (2008).
  58. Veljkovic N, Glisic S, Prljic J, Perovic V, Botta M, Veljkovic V. Discovery of new therapeutic targets by the informational spectrum method. Curr Protein Pept Sci. 9, 493 (2008).
  59. Veljkovic V, Veljkovic N, Muller CP, Müller S, Glisic S, Perovic V, Köhler H. Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control. BMC Struct Biol., 9, 21 (2009).
  60. Veljkovic V, Niman HL, Glisic S, Veljkovic N, Perovic V, Muller CP. Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor. BMC Struct Biol., 9, 62 (2009).
  61. Veljkovic M, Dopsaj V, Stringer WW, Sakarellos-Daitsiotis M, Zevgiti S, Veljkovic V, Glisic S, Dopsaj M. Aerobic exercise training as a potential source of natural antibodies protective against human immunodeficiency virus-1. Scand J Med Sci Sports., 20, 469 (2010).
  62. Tintori C, Veljkovic N, Veljkovic V, Botta M. Computational studies of the interaction between the HIV-1 integrase tetramer and the cofactor LEDGF/p75: insights from molecular dynamics simulations and the informational spectrum method. Proteins, 78, 3396 (2010).
  63. Veljkovic M, Branch DR, Dopsaj V, Veljkovic V, Veljkovic N, Glisic S, Colombatti A. Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer? Med Hypotheses, 77, 404 (2011).
  64. Veljkovic M, Dopsaj V, Dopsaj M, Branch DR, Veljkovic N, Sakarellos-Daitsiotis MM, Veljkovic V, Glisic S, Colombatti A. Physical Activity and Natural Anti-VIP Antibodies: Potential Role in Breast and Prostate Cancer Therapy PLoS One. 2011;6(11):e28304.
  65. Veljkovic N, Glisic S, Perovic V, Veljkovic V. The role of long-range intermolecular interactions in discovery of new drugs. Exp. Opin. Drug Disc. 2011;;6(12):1263.
  66. Glisic S, Veljkovic N, Jovanovic Cupic S, Vasiljevic N, Prljic J, Gemovic B, Perovic V, Veljkovic V. Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype b. Protein J. 2012;31(2):129
  67. Vergara-Alert J, Argilaguet JM, Busquets N, Ballester M, Martín-Valls GE, Rivas R, López-Soria S, Solanes D, Majó N, Segalés J, Veljkovic V, Rodríguez F, Darji A. Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model. PLoS One. 2012;7(7):e40524.
  68. Maga G, Veljkovic N, Crespan E, Spadari S, Prljic J, Perovic V, Glisic S, Veljkovic V. New in silico and conventional in vitro approaches to advance HIV drug discovery and design. Expert Opin Drug Discov. 2013;8(1):83.
  69. Perovic VR, Muller CP, Niman HL, Veljkovic N, Dietrich U, Tosic DD, Glisic S, Veljkovic V. Novel phylogenetic algorithm to monitor human tropism in Egyptian H5N1-HPAIV reveals evolution toward efficient human-to-human transmission. PLoS One. 2013 Apr 26;8(4):e61572.
  70. Veljkovic N, Glisic S, Prljic J, Perovic V, Veljkovic V. Simple and General Criterion for “In Silico” Screening of Candidate HIV Drugs. Curr Pharm Biotechnol. 2012: 14:85.
  71. Veljkovic V, Glisic S, Veljkovic N, Bojic T, Dietrich U, Perovic VR, Colombatti A. Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism. Vaccine 2014; 32:6569.
  72. Veljkovic V, Loiseau PM, Figadere B, Glisic S, Veljkovic N, Perovic VR, Cavanaugh DP, Branch DR. Virtual screening for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection, F1000Res. 2015;4:34.
  73. Veljkovic V, Glisic S, Muller CP, Scotch M, Branch DR, Perovic VR, Sencanski M, Veljkovic N, Colombatti A. In silicoanalysis suggests interaction between Ebola virus and the extracellular matrix. Front Microbiol. 2015;6:135.
  74. Veljkovic N, Vucicevic J, Tassini S, Glisic S, Veljkovic V, Radi M. Preclinical discovery and development of maraviroc for the treatment of HIV. Expert Opin Drug Discov. 2015;10:671.
  75. Schmier S, Mostafa A, Haarmann T, Bannert N, Ziebuhr J, Veljkovic V, Dietrich U, Pleschka S. In Silico Prediction and Experimental Confirmation of HA Residues Conferring Enhanced Human Receptor Specificity of H5N1 Influenza A Viruses. Sci Rep. 2015;5:11434.
  76. Glisic S, Paessler S, Veljkovic N, Perovic VR, Prljic J, Veljkovic V. Improving attrition rates in Ebola virus drug discovery. Expert Opin Drug Discov. 2015;10:1025.
  77. Veljkovic V, Goeijenbier M, Glisic S, Veljkovic N, Perovic VR, Sencanski M, Branch DR, Paessler S. In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease. F1000Res. 2015;4:104.
  78. Veljkovic V, Paessler S, Glisic S, Prljic J, Perovic VR, Veljkovic N, Scotch M. Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic. Front Microbiol. 2015;6:1456.
  79. Veljkovic V, Paessler S. Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection. F1000Res. 2016: doi: 10.12688/f1000research. 8102.2.
  80. Jiang Y et al. An expanded evaluation of protein function prediction methods shows an improvement in accuracy. Genome Biol. 2016;17:184.
  81. Veljkovic V, Veljkovic N, Paessler S, Goeijenbier M, Perovic V, Glisic S, Muller CP. Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China. PLoS One. 2016;11:e0165451.
  82. Veljkovic V, Glisic S, Perovic V, Paessler S, Veljkovic N, Nicolson GL. Simple chemoinformatics criterion using electron donor-acceptor molecular characteristics for selection of antibiotics against multi-drug-resistant bacteria. Discoveries 2016; 4: e64.